While research has predominantly centered on CD4+CD25+FOXP3+ T cells, it is plausible to speculate that CD4+CD25+Foxp3- T cells could potentially influence tumor progression and patient outcomes through analogous mechanisms, thereby warranting further investigation into their role in the complex tumor immune microenvironment. The gene discussed is CD4; the disease is neoplasm.